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Lifelong antiretroviral therapy (ART) reduces mother-to-child HIV transmission (MTCT) and
improves maternal health. Data on the outcomes of HIV-exposed infants (HEI) compared to
their unexposed counterparts in the era of universal ART is limited. We compared birth and
6-week outcomes among infants born to HIV-positive and HIV-negative women in Lesotho.
Methods
941 HIV-negative and 653 HIV-positive pregnant women were enrolled in an observational
cohort to evaluate the effectiveness of prevention of mother-to-child HIV transmission
(PMTCT) program after implementation of universal maternal ART in 14 health facilities.
Pregnancy, delivery, birth, and 6-week data were collected through participant interviews
and medical record review. DNA PCR testing for HEI was conducted within 2 weeks of birth
and at around 6 weeks of age. Data were analysed to estimate the distribution of birth out-
comes, mortality, HIV transmission and HIV-free survival at 6 weeks.
Results
HIV-positive women were older (mean age of 28.7 vs. 24.4 years) and presented for antena-
tal care earlier (mean gestational age of 23.0 weeks vs 25.3 weeks) than HIV-negative
women. Prematurity was more frequent among HEI, 7.8% vs. 3.6%. There was no differ-
ence in rates of congenital anomalies between HEI (1.0%) and HIV-unexposed infants
(HUI) (0.6%). Cumulative HIV transmission was 0.9% (N = 4/431) (95% CI:0.25–2.36) at
birth and 1.0% (N = 6/583) (95% CI:0.38–2.23) at 6 weeks. Overall mortality, including
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stillbirths, was 5.2% and 6.0% by 6 weeks for HUI and HEI respectively. Among liveborn
infants, 6-week HIV-free survival for HEI was 95.6% (95% CI:93.7–97.1) compared to
96.8% (95% CI:95.4–97.9) survival for HUI.
Conclusions
Implementation of universal maternal ART lowers MTCT at 6 weeks of age with no differ-
ences in congenital anomalies or early mortality between HIV exposed Infants and HIV
unexposed infants. However, HIV exposed infants continue to have high rates of prematurity
despite improved maternal health on ART.
Introduction
Effective prevention of mother to child transmission (PMTCT) programs offering universal
life-long antiretroviral therapy (ART) reduce HIV transmission to children from their mother
and improve maternal health [1,2]. A critical question remains as to whether the reduction in
MTCT rates and improvement in maternal health are coupled with improvement in birth out-
comes and survival among HIV-exposed infants (HEI) to match those of HIV-unexposed
infants (HUI).
There have been conflicting data reported on birth outcomes among HIV-positive women
who are on lifelong ART compared to HIV negative women. Some studies found that adverse
birth outcomes, such as increased preterm deliveries, stillbirths and low birth weight, occurred
more frequently among HEI [3–8]. Other studies found no association between use of ART
and adverse birth outcomes [9,10].
Intrauterine and perinatal HIV transmission measurement in the era of lifelong ART is lim-
ited. In Rwanda, a study measuring HIV-free survival in a cohort of HEI, found a 6-week
Mother to child transmission rate of 0.5% (95% CI:0.2–1.6) demonstrating the effectiveness of
lifelong ART for HIV-positive pregnant women in preventing perinatal HIV transmission
[11]. UNAIDS spectrum data in Lesotho reported an estimated 6-week transmission of 6.9%
in 2016 [1].
Lesotho is a mountainous country in southern Africa with one of the highest HIV preva-
lence documented in the world. The Lesotho Ministry of Health implemented universal ART
for all HIV-positive pregnant women in 2013 using a once-daily fixed dose combination of
tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFZ) [12,13]. HIV-
exposed infants are given nevirapine (NVP) for 6 weeks after birth.
The roll out of lifelong ART for all pregnant women in Lesotho provided a unique opportu-
nity to determine its effect on birth outcomes and survival of infants born to HIV-positive
mothers compared with a similar cohort of HIV-negative mothers and their HIV-unexposed
infants. The study also assessed the effectiveness of the Lesotho PMTCT program in reaching
the goal of the virtual elimination of new pediatric HIV infections in selected sites in Lesotho.
Methods
Design
HIV-positive and HIV-negative pregnant women attending routine antenatal care (ANC) ser-
vices were enrolled in a prospective observational cohort study from June 2014 to February
2016. Study personnel captured demographic, social, and medical information through
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participant interviews and extraction of medical record information during pregnancy, and at
delivery, birth and 6 weeks postpartum.
Setting
The study was conducted in 3 districts in Lesotho–Botha-Bothe, Thaba-Tseka and Mohale’s
Hoek. These districts were selected to include areas with varying levels of PMTCT service
delivery coverage, and heterogeneity in health-seeking behavior due to variances in terrain
(lowlands, foothills, mountains). We included all 5 hospitals in these districts and randomly
selected 9 medium volume (100–200 ANC women/year) or high (>200 ANC women/year)
health centers to be included in the study.
Population and enrollment
Eligible HIV-positive and HIV-negative pregnant women attending ANC in the study health
facilities were recruited for this study. They were eligible for study enrollment if they resided
in the area, planned to continue to receive services at the facility following delivery, were will-
ing to have their infant co-enrolled after birth, and were willing to provide written informed
consent. Population proportional sampling was used to estimate the enrollment target at each
of the 14 study facilities. The sample size for HIV-positive women was calculated based on a
4% estimated HIV transmission at 6–8 weeks in Lesotho at the time of study initiation with a
precision of 1.4% [12]. Consecutive consenting women were enrolled until the sample size was
reached. HIV-negative women were enrolled into an HIV seroincidence cohort study with
scheduled repeat HIV testing at 36 weeks gestation, delivery, and every 3–6 months postpar-
tum until 24 months postpartum [14].
Data collection
Study data were collected by trained study nurses through structured interviews and by
abstraction of data from clinical and laboratory records. Mother-infant pair information such
as demographic variables, date of last menstrual cycle, HIV status of spouse, disclosure of HIV
status was collected through structured interviews with the pregnant women. General health
and clinical history, ARV use and toxicity, adherence, retention in care, family planning, infant
feeding practices and infant growth were extracted from the women medical charts and clinic
registers. Electronic tablets were used to enter data directly into a web-based database
(SurveyCTO).
Gestational age at birth was estimated by the time between the date of last menstrual period
given by the women at first ANC and the date of birth. Very preterm birth was defined as
infant born at a gestational age of 28–32 weeks while preterm birth was infant born after 32
weeks but before 37 weeks [15]. In addition, miscarriage was defined as loss of pregnancy
before the gestational age of 28 weeks and stillbirth was considered when the pregnancy was
lost after 28 weeks [16].
Laboratory methods
Blood samples were collected from a subset of HEI at or within 2 weeks of birth and from all
HEI at 6–8 weeks of age to determine their HIV infection status. Trained nurses obtained
blood from infants by heel prick, which was spotted directly onto filter paper to create a dried
blood spot for HIV DNA PCR testing as per the standard Ministry of Health (MOH) protocol.
HIV testing was performed by the national reference laboratory using the Roche COBAS
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Ampliprep/COBAS TaqMan HIV-1 qualitative test (v2.0). Test results were obtained directly
from the laboratory and entered into the study database.
Statistical analysis
Quantitative data analysis was performed using STATA version 15.1 (College Station, TX,
USA). We summarized categorical variables using frequencies and percentages of participants
and continuous variables using means (+/- standard deviation). Maternal baseline characteris-
tics were stratified by HIV status at enrollment. We compared birth outcomes between HIV-
exposed and HIV-unexposed infants. HIV-free survival was estimated as the proportion of
children alive and HIV-negative among all exposed children. The precision around survival
estimates was assessed by 95% confidence intervals. We used the Kaplan Meier curves to
graphically display infant mortality, infection, and HIV free survival. We performed complete
case analysis, and missing data were not imputed.
Ethical considerations
The study was approved by the Lesotho Ministry of Health Research and Ethics Committee,
the Baylor College of Medicine Children’s Foundation Lesotho Institutional Review Board
(IRB), and the George Washington University Committee on Human Research IRB. All
women were informed of the study protocol, requirements, and risks and benefits, and pro-
vided written informed consent to participate in the study.
Results
Participant characteristics
A total of 1594 pregnant women (941 HIV-negative and 653 HIV-positive) were enrolled in
the study with their infants (Fig 1). Eight HIV negative women seroconverted before delivery.
Delivery information was available for 95.4% of HIV positive women (623/653 and 92.2% of
HIV negative women (868/941). 623 HIV positive women gave birth to 631 HIV exposed
infants (HEI) and 868 HIV negative women gave birth to 879 HIV unexposed infants (HUI).
Six week-follow-up information was available for 577 and 831 HEI and HUI respectively.
Characteristics of HIV-positive and HIV-negative study women at enrollment are pre-
sented in Table 1. HIV-positive pregnant women were older than their HIV-negative counter-
parts with a mean age of 28.7 (+/- 5.5) compared to 24.4 (+/- 5.7) years. HIV-positive women
also presented earlier for ANC at a mean gestational age of 23.0 (+/- 8.7) weeks compared to
25.3 (+/- 8.2) weeks. Overall, 83.5% of the women were married, and 59.3% had disclosed their
HIV-status to their partner/husband. Concerning HIV status of spouses, 4.2% of HIV negative
women had HIV positive partners while 29.6% of HIV positive women had an HIV negative
partner.
Among HIV-positive women, 97.8% were receiving ART at enrollment with 84.2% receiv-
ing the TDF/3TC/EFV first-line regimen. Among the 619 women with data available on the
timing of ART, 249 (40.2%) initiated ART before conception and 370 (59.8%) initiated ART
after conception.
Birth outcomes
Overall, 91.6% of study women delivered in a health facility and 96.8% (n = 1443) of infants
were born alive (Table 2). There was no difference in the proportion of infant stillbirths, how-
ever, HIV-positive women were more likely to have had a macerated stillbirth (consistent with
antepartum death), while HIV-negative women were more likely to have had an intrapartum
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death (fresh stillbirth or a liveborn infant who died within two hours of delivery). The risk of
premature birth in HEI was more than double the risk of prematurity in HUI (7.8% vs 3.6%).
The risk of very premature births (<32 weeks gestational age) was also substantially higher in
HEI (2.2%) compared to HUI (0.4%).
Of the 249 women who initiated ART pre-conception, 24 (9.6%) had premature babies
compared to 27 (7.3%) among the 370 women who initiated ART post-conception. The rates
of very low weight (<1.5kgs) and low birth weight (<2.5 kgs) among women who initiated
ART before conception were 1.7% and 11.6% respectively compared to 1.2% and 11.9%
among women who initiated ART after conception.
Fig 1. Study enrollment for comparison of 6-week PMTCT outcomes for HEI and HUI in the era of lifelong ART.
https://doi.org/10.1371/journal.pone.0226339.g001
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The rate of congenital anomalies was 0.6% and 1% among HEI and HUI respectively.
Infant survival
There were no substantial differences in the rates of infant survival at 6 weeks of age by infant
HIV exposure status (Fig 2 and Table 3). When including all deaths (liveborn plus stillbirths),
the estimated survival rates were 94.8% (95% CI: 93.1–96.1) among HUI and 94.0% (95% CI:
91.8–95.7) among HEI. Analysis of postnatal deaths only (excluding stillbirths), yielded esti-
mated survival rates of 96.8% (95% CI: 95.4–97.9) and 96.7% (95% CI: 95.0–98.0) for HUI and
HEI respectively. Adjusting for maternal mortality and gestational age at first ANC visit, infant
HIV exposure status was not associated with early infant mortality (aOR = 1.06, 95% CI: 0.56–
1.99).
Mortality and HIV-free survival among HEI
Six infants were diagnosed with HIV infection by 6 weeks of age, including 4 diagnosed at
birth, and 2 diagnosed at 6 weeks of age (Table 4). The estimated HIV transmission rate
among those tested at birth was 0.9% (95% CI: 0.25–2.36) and by 6 weeks the overall HIV
transmission was 1.0% (95%CI: 0.38–2.23). The estimated HIV-free survival including still-
births was 92.8% (95% CI: 90.5–94.8), and 95.6% (95% CI: 93.7–97.1) when stillbirths were
excluded.
Table 1. Characteristics of study women at enrollment.
Maternal HIV Status Total Mothers
HIV-negative (N = 941) HIV-positive (N = 653�) Total (N = 1593)
n (%) n (%) n (%)
Maternal age in years (mean +/- SD) 24.4 +/- 5.7 28.7 +/- 5.5 26.0 +/- 6
Gestational age at first ANC in weeks (mean, SD) 25.3 +/- 8.2 23.0 +/- 8.7 24.4 +/- 8.5
Marital Status: Married 801 (85.1) 528 (81.0) 1329 (83.4)
Mother disclosed HIV status to husband/partner 521 (55.4) 422 (64.9) 943 (59.3)
Missing Data 0 3 3
Maternal ARV Regimen at enrollment
TDF+3TC+EFV N/A 548 (84.2) 548 (84.2)
TDF+3TC+NVP N/A 25 (3.8) 25 (3.8)
AZT+3TC+EFV N/A 28 (4.3) 28 (4.3)
AZT+3TC+NVP N/A 29 (4.5) 29 (4.5)
ART-other regimens N/A 7 (1.1) 7 (1.1)
None N/A 14 (2.2) 14 (2.2)
Missing data N/A 1 1
Husband/Partner’s HIV Status
Positive 19 (4.2) 230 (68.9) 249 (31.8)
Negative 422 (94.0) 99 (29.6) 521 (66.5)
Unknown 8 (1.8) 5 (1.5) 13 (1.7)
Not tested 492 318 810
Husband/Partner Taking ARVs
Yes 14 (73.7) 166 (72.2) 180 (72.3)
No 5 (26.3) 63 (27.4) 68 (27.3)
Unknown 0 1 (0.6) 1 (0.4)
�One woman was enrolled but excluded from analysis due to missing enrolment questionnaire data
https://doi.org/10.1371/journal.pone.0226339.t001
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Five of the 6 HIV-infected infants had mothers that were initiated on ART post-conception
(Table 5). Five of the mothers of infected infants had records of viral load at delivery and of
these, 4 women had viral loads above 100,000 copies/ml. All mothers were on a TDF/3TC/EFZ
regimen as per the national guidelines.
At 6 weeks, the mortality rate was higher among premature babies 24.6% (17/69) compared
to mature infants 2.1% (29/1391). There was also a difference in 6-8-week mortality between
low birth weight infants compared to normal birth weight infants (7.0% vs. 1.9%). Very low
birth weight infants had higher risk of death within 6–8 weeks compared to infants born
weighing at least 1.5kgs or more (30% vs 2.2%).
Discussion
This is the first prospective cohort study in Lesotho comparing birth and 6-week outcomes
between HEI and HUI in a large cohort of HIV-positive and negative women and their infants.
We found that birth outcomes of HEI were similar to those of HUI except for the frequency of
prematurity, which was found to be significantly higher among HEI. While prematurity
among HEI has been reported in several other studies [17–19], there have been few studies
Table 2. Birth outcomes by mother’s HIV status at delivery.










Miscarriage� 7 (0.8) 10 (1.6) 17 (1.1) 0.16
Mode of Delivery
Vaginal 748 (86.6) 525 (84.8) 1273(85.9) 0.11
Cesarean section 116 (13.4) 94 (15.2) 210(14.1)
Place of delivery
Health facility 786/858 (91.6) 560/620(90.3) 1346(91.1)
Home 67 (7.8) 53 (8.5) 120 (8.1)
Other 5 (0.5) 7 (1.1) 12 (0.8)
Missing data 10 2 12
Birth Outcome
Liveborn† 840 (96.8) 603 (96.8) 1443 (96.8)
Antepartum death 5 (0.6) 12 (1.9) 17 (1.1) 0.01
Intrapartum death 23 (2.6) 8 (1.3) 31 (2.1)
Newborn Maturity
Mature 835 (96.0) 574 (91.7) 1409 (94.2) 0.001
Premature 35 (4.0) 52 (8.3) 87 (4.8)
Very Premature delivery (<32 wks) 3 (0.4) 13 (2.2) 16 (1.1) 0.001
Premature delivery (<37 wks) 31 (3.6) 48 (7.8) 79 (1.6) <0.01
Missing data 5 1 6
Newborn with congenital anomalies 9 (1.0) 4 (0.6) 13 (0.9 0.56
Birth Weight in kilograms
Normal weight 736 (90.8) 514(88.3) 1250(89.7) 0.15
Low Birth Weight (<2.5 kg) 75 (9.2) 68(11.7) 143(10.3)
Very Low Birth Weight (<1.5 kg) 7 (0.9) 8 (1.4) 15(1.1) 0.43
�There were no miscarriages or stillbirths recorded among the 8 women who seroconverted between enrollment and delivery
†This does not include babies who were born alive and died with two hours.
https://doi.org/10.1371/journal.pone.0226339.t002
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conducted within routine health systems with large numbers of both HIV-positive and HIV-
negative women in the era of lifelong ART for all pregnant women with TDF-based ART regi-
mens. In our study, infant prematurity and low birth weight were not significantly different
among women who initiated ART before conception compared to those who initiated ART
after conception. This is consistent with other studies that reported no relationship between
preconception ART and preterm delivery [17,18]. However, in a systematic review and meta-
analysis of adverse pregnancy outcomes and timing of initiation of ART, Uthman et. al
reported significantly higher risk of prematurity among HEI whose mothers initiated ART
before conception compared to those who initiated ART after conception (pooled RR 1.20,
95%CI 1.01–1.44) [8].
As recommended for first-line treatment in Lesotho, 88% of HIV-positive women were on
TDF-based ART regimens. In a systematic review and meta-analysis looking at safety of TDF-
based regimens in pregnancy for HIV-positive women and their infants, the rates of prematu-
rity and stillbirths were significantly lower among women on TDF-based ART compared to
other ART regimens [20, 21]. However, even with the use of TDF regimens, our study showed
that HEI still had a higher risk of prematurity compared to HUI.
We found that HEI were more likely to die antepartum (1.9% versus 0.6%), consistent with
medical complications, while HUI were more likely to die during the intrapartum period
(2.6% versus 1.3%), consistent with obstetrical complications. However, it may be important
to note that these women were followed up only from their first ANC and we may have missed
some of the antepartum deaths which occurred before women were enrolled in the study. A
number of studies have explored causes of antepartum death among HEI. In South Africa and
Botswana, maternal vascular malperfusion was more frequent among HIV-positive women
Fig 2. Survival of HUI and HEI at six weeks of age including and excluding stillbirths.
https://doi.org/10.1371/journal.pone.0226339.g002










Including stillbirths 46/877 (5.2%) 94.8% [93.1–96.1] 38/631 (6.0%) 94.0% [91.8–95.7]
Excluding stillbirths 27/858 (3.2%) 96.8% [95.4–97.9] 20/613 (3.3%) 96.7% [95.0–98.0]
https://doi.org/10.1371/journal.pone.0226339.t003
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and placenta insufficiency associated with hypertension accounted for most stillbirths [22,23].
In our study, postpartum infant mortality at 6 to 8 weeks was independently associated with
gestational age, but not with HIV exposure status.
We found one of the lowest 6-week HIV transmission rates (1.0%) reported in Lesotho cou-
pled with very high HIV-free survival among liveborn infants at 6 weeks of age. This is a signif-
icant improvement compared to the estimated 6-week transmission of 7% reported in Lesotho
in 2016 and in other countries in the region [1, 24]. Two-thirds of the HIV-positive infants
identified were infected in utero. Most women presented for their first ANC visit toward the
end of the second trimester, contrary to the WHO recommendation for women to present
during the first trimester. Early ANC visits are especially important for HIV-positive pregnant
women because earlier ART initiation may further reduce MTCT in utero [12,25]. This was
buttressed by the findings that almost all women who transmitted HIV to their infants had a
high viral load despite being on ART. Therefore, we agree with Smith et. al that it is essential to
maximize viral suppression for HIV-positive women on ART [25].
Our findings indicate that the current universal ART program within the setting of routine
care is effective. Implementation of this program showed that high ANC utilization, and high
uptake of ART during pregnancy, including a high proportion of facility-based deliveries, col-
lectively led to improved pregnancy outcomes among HIV-positive women. Our study also
demonstrates the importance of incorporating implementation research to document program
effectiveness within routine, public health settings. Lesotho’s experience shows that when
PMTCT programs are well implemented, routine program setting can achieve high effective-
ness, comparable to more controlled research settings.
A limitation of our study is that it measured birth outcomes and 6-week HIV-free survival
in a facility-based population and may have missed women and children who did not seek
care in health facilities. We may have also missed women who lost pregnancies early. In addi-
tion, our study may have potential systematic errors arising from estimation of gestational age
with the potential of misclassifying baby’s maturing at delivery. However, since ANC atten-
dance in Lesotho is higher than in many African countries, we believe that the results are










Including stillbirths 38/627 (6.1%) 6/581 (1.0%) 44/613 (7.2%) 92.8% [90.4–94.7]
Excluding stillbirths 20/609(3.3%) 6/581 (1.0%) 26/595(4.4%) 95.6% [93.7–97.1]
https://doi.org/10.1371/journal.pone.0226339.t004










Maternal duration on ART
before delivery (months)
Infant maturity and






1 23 32 Pre-conception 32.5 Mature—2.4 TLE 36,881
2 22 24 Post-conception 3.5 Mature—3.5 TLE 109,000
3 32 18 Post-conception 5.6 Mature—3.5 TLE 428,054
4 18 18 Post-conception 4.6 Mature—2.8 TLE 320,000
5 23 10 Post-conception 6.9 Mature—2.8 TLE 100,062
6 25 29 Post-conception 2.6 Mature—2.9 TLE -
+All mothers were initiated on Tenofovir-Lamivudine-Efavirenz (TLE) after HIV diagnosis and remained on this regimen throughout the study.
https://doi.org/10.1371/journal.pone.0226339.t005
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reflective of the Lesotho context [26, 27]. The successful reduction of perinatal HIV transmis-
sion that we report may not be comparable in areas with lower ANC attendance and low rates
of facility-based deliveries. Additionally, study sites were purposively selected so the findings
may not be generalizable to the whole country of Lesotho, especially to low volume facilities,
which were not included in the study. However, the purposive selection of sites from the three
geo-ecological settings in Lesotho (highlands, foothills, lowlands) does account for the vari-
ances in health-seeking behaviors.
Conclusion
Implementation of universal maternal ART was associated with low MTCT among infants at 6
weeks of age with no differences in congenital anomalies or early mortality between HEI and
HUI. However, HEI continue to have increased rates of prematurity even in the era of lifelong
combination ART.
Supporting information
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